Sign up
Log in
Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
Share
Listen to the news
  • New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups
  • New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure
  • In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients
  • The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved